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The gene encoding interleukin-2 (IL-2) contains a sequence 52 to 326 nucleotides upstream of its
transcriptional initiation site that promotes transcription in T cells that have been activated by costimulation
with tetradecanoyl phorbol myristyl acetate (TPA) and phytohemagglutinin (PHA). We found that the
ubiquitous transcription factor, Oct-1, bound to two previously identified motifs within the human IL-2
enhancer, centered at nucleotides -74 and -251. Each site in the IL-2 enhancer that bound Oct-1 in vitro was
also required to achieve a maximal transcriptional response to TPA plus PHA in vivo. Point mutations within
either the proximal or distal octamer sequences reduced the response of the enhancer to activation by 54 and
34%, respectively. Because the murine T-cell line EL4 constitutively expresses Oct-2 and requires only TPA to
induce transcription of the IL-2 gene, the effect of Oct-2 expression on activation of the IL-2 promoter in Jurkat
T cells was determined. Expression of Oct-2 potentiated transcription 13-fold in response to TPA plus PHA and
permited the enhancer to respond to the single stimulus of TPA. Therefore, both the signal requirements and
the magnitude of the transcription response of the IL-2 promoter can be modulated by Oct-2.
The gene encoding interleukin-2 (IL-2) is one of a family of
genes whose transcription is induced by activation of T
lymphocytes (22, 44). Although T-cell activation is a com-
plex process in vivo, involving the binding of antigen and
costimulation by lymphokines (19, 26, 28, 41, 43), activation
of T cells in tissue culture can be accomplished by stimula-
tion with phytohemagglutinin (PHA), which induces the
same increase in intracellular free calcium as does the
binding of antigen (12, 14, 33, 39, 40), and tetradecanoyl
phorbol myristyl acetate (TPA), which substitutes for lym-
phokines (40).
A fragment of the IL-2 promoter extending 52 to 326
nucleotides from the transcriptional initiation site functions
as a T-cell-specific enhancer, strictly modulated by the
combined stimuli ofTPA plus PHA (5, 11). These sequences
contain essential binding sites for the transcription factors
NF-KB (32) and NFAT (34). Two additional factors, NF-
IL2-A, and NF-IL2-D, bind sequences in the IL-2 promoter
centered at -74 and -251 (7; Fig. 1). When assayed by
electrophoresis through polyacrylamide gels under native
conditions, oligonucleotides containing these sequences
cross-compete for the formation of a single complex, indi-
cating that NF-IL2-A and NF-IL2-D are likely the same
protein (6). Deletion of the sequences to which NF-IL2-A
and NF-IL2-D bind results in a 95 and 59% reduction in the
ability of the promoter to respond to stimulation in the
context of an IL-2 promoter chloramphenicol acetyltransfer-
ase (CAT) construct, and multimers of a 30-base-pair (bp)
sequence (-65 to -94) containing the NF-IL2A site confer
calcium responsiveness upon the fibrinogen promoter (6). In
addition, coincident with T-cell activation, a major DNase
I-hypersensitive site appears at -85 (36), whose formation is
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blocked if T cells are activated in the presence of cyclosporin
A (36), a compound that inhibits the production of IL-2 in T
cells activated by PHA or antibodies against T3 (2). Conse-
quently, proteins that bind this 30-bp sequence are involved
directly in the activation pathway. The close similarity
between sequences in the NF-IL2-A- and NF-IL2-D-binding
sites (ATGTAAAACA and ATGCAATTAA, respectively)
and those of the canonical octamer sequence found in many
transcription control systems (ATGCAAATNA) led us to
investigate whether NF-IL2-A and NF-IL2-D are actually
the octamer-binding protein, Oct-1.
The octamer sequence, ATGCAAAT, was originally dis-
covered in the promoter of immunoglobulin genes (7, 29, 30),
and deletion analysis proved that the octamer motif is
required for specific transcription in B cells (1, 3, 7, 8, 9, 30).
Octamer motifs also function as essential elements in the
promoters of genes transcribed outside the B-lymphocytic
lineage, such as those regulating the expression of histone
H2B and the Ul and U2 small nuclear RNAs (2, 20, 24, 37).
Although octamer-binding sites normally have the sequence
ATGCAAATNA, closely related sequences also serve as
octamer-binding sites; ATGCTAATGA, for instance, found
in the promoter of the herpes simplex virus type 1 gene
encoding IEllOK, binds Oct-1 efficiently (27). In this report,
we demonstrate that the cellular factors NF-IL2-A and
NF-IL2-D are indistinguishable from Oct-1 and that their
specific binding sites are important for the TPA- and PHA-
inducible properties of the IL-2 enhancer. We also investi-
gate the effect of Oct-2, a second octamer-binding protein
expressed mainly in B lymphocytes, on the response of the
IL-2 enhancer to TPA or TPA plus PHA.
MATERIALS AND METHODS
Preparation of nuclear extracts. Nuclear extracts were
prepared according to the procedure outlined by Dignam et
al. (4) and stored at -800C.
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FIG. 1. Binding sites for transcription factors in a PHA-plus-TPA-responsive portion of the IL-2 promoter. Arrows indicate that octamer
sequences are positioned in opposing orientations.
Gel mobility shift assays. At room temperature, 0.5 pug of
nuclear extract was incubated with 20 fmol of probe in 20 ,ul
of a solution containing 3 pug of poly(dI-dC), 2% glycerol, 1.0
mM dithiothreitol, 20 mM NaCl, 10 mM Tris (pH 7.5), 1.0
mM EDTA, 30 pug of bovine serum albumin, and 5% buffer D
(20 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic
acid [HEPES; pH 7.9], 25% glycerol, 0.42 M NaCl, 1.5 mM
MgCl2, 0.2 mM EDTA, 0.5 mM phenylmethylsulfonyl fluo-
ride, 0.1% aprotinin, 0.5 mM dithiothreitol). The DNA-
protein complexes were separated by electrophoresis
through 4% acrylamide gels, using nondenaturing conditions
and a buffer containing 6.8 mM Tris (pH 7.5), 3.4 mM
sodium acetate, and 1.0 mM EDTA. The rabbit anti-Oct-2
serum that blocked the formation of complexes containing
octamer protein was prepared as described previously (16)
against an Oct-2-protein A fusion protein designated
PAOct-2 (17). A 0.5-pu volume of anti-Oct-2 was used per
assay.
Glycerol gradient sedimentation. A 100-pd volume of nu-
clear extract from BJA/B cells (6.0 mg/ml) was diluted with
100 pu1 of buffer D containing no glycerol. The final concen-
tration of glycerol was 10%. This mixture was layered on a
5-ml glycerol gradient (15 to 30%) formed in buffer D. The
gradient was centrifuged at 40,000 rpm in an SW50.1 rotor
for 17 h, and 20 fractions were isolated by dripping the
contents from the bottom of the tube. The presence of Oct-2
was monitored by using the gel mobility shift assay, and
fractions 8 and 9 contained 80% of the activity.
DNase I protection assays. DNase I footprinting (15) was
performed by using 10 fmol of probe and 1.2 ,ug of poly(dI-
dC) per reaction. In reactions containing Oct-2, partially
purified by centrifugation through a glycerol gradient, 25 ,u1
of fraction 8 or 9 was used. In those reactions containing
recombinant Oct-2, 20 ng was used. All reactions were
subjected to digestion with 5 ng of DNase I on ice for 1 min.
Methylation interference assays. Dimethyl sulfoxide was
used to partially methylate 32P-end-labeled DNA (21), and
the radioactive DNA fragment was used in the gel mobility
shift assay. The DNA contained in the complexed and free
pools was identified by autoradiography of the wet gel,
which was wrapped in Saran wrap. These bands were
excised from the gel and electroeluted for 1.0 h to recover
the DNA. The eluted DNA was extracted consecutively with
phenol and then with phenol-chloroform (1:1) and was
recovered by precipitation with 2.5 volumes of ethanol. The
pellet was redissolved in 100 p.1 of 1.0 M piperidine, incu-
bated at 90°C for 30 min, and lyophilized. The products were
analyzed by electrophoresis through a 12% polyacrylamide
gel containing 8.0 M urea.
Transfection and stimulation of Jurkat T cells. Jurkat T
cells were grown in RPMI medium containing 10% fetal
bovine serum. DEAE-dextran-mediated transfection (13)
was used to introduce plasmid DNA. In all cases, a 15-,ug/ml
concentration of either pIL2CAT or pIL2fosCAT was used.
The cells were stimulated with either TPA (50 ng/ml) alone
or with TPA (50 ng/ml) and PHA (2 ,ug/ml) for 10 h. CAT
activity in cellular extracts was determined by measuring
catalytic transfer of the acetyl group from ["4C]acetyl coen-
zyme A to chloramphenicol. The amount of extract and
duration of incubation with substrate varied as indicated in
the figure legends. Reaction products were resolved by
ascending chromatography, and 14C-acetylated chloram-
phenicol was quantitated by scintillation spectroscopy.
Background in the CAT assays included both acetylated
chloramphenicol and impurities in the [14C]chloramphenicol
that comigrated with acetylated chloramphenicol.
Mutagenesis of pIL2fosCAT. The technique of gapped
heteroduplex mutagenesis (18) was used to make specific
nucleotide changes in both the proximal and distal IL-2
octamer motifs. Oligonucleotides TCGACATATGTGTAA
GGCCTAAAACAT1TTGAC and TCGACAGCTCTAAT
TCATGCAATTAACGCCTTC were used respectively for
creating the mutants at these sites.
RESULTS
Two sequences in the IL-2 promoter bind cellular proteins
that exhibit electrophoretic properties identical to those of
Oct-1, Oct-2, and Oct-2B. A variety of techniques were used
to demonstrate that octamer proteins bind to two sites in the
IL-2 promoter. First, complexes formed between IL-2 en-
hancer DNA and proteins extracted from purified nuclei
were analyzed by separation through 4% polyacrylamide
gels under nondenaturing conditions. The mobility of pro-
tein-DNA complexes formed with probes from the IL-2
promoter was compared with the mobility of those formed
with a 145-bp fragment of the immunoglobulin heavy-chain
promoter, designated VH, which contains a consensus oc-
tamer motif. The VH probe formed a complex with Oct-1 in
the presence of nuclear extracts from both the human T-cell
line, Jurkat, and the human carcinoma line, HeLa, and with
Oct-1, Oct-2, and Oct-2B in nuclear extracts from the mature
human B-cell lymphoma cell line, BJA/B (Fig. 2A, lanes 1, 4,
and 7). Probes containing IL-2 promoter sequences spanning
-60 to -145 bp (proximal IL-2 probe; Fig. 2B) and -235 to
-350 (distal IL-2 probe; Fig. 2C) each formed a complex
(designated 1; lanes 1 and 7) with a protein in nuclear
extracts from Jurkat and HeLa cells that appeared indistin-
guishable from that formed between Oct-1 and the VH probe.
Likewise, when incubated with extracts from BJAIB nuclei,
the proximal and distal IL-2 probes formed complexes 1, 2,
and 3, which comigrated with the Oct-1, Oct-2, and Oct-2B
complexes (lanes 4). Each complex behaved as if it con-
tained an octamer-binding protein because the formation of
each was inhibited by inclusion of 20 ng of an oligonucleotide
containing the octamer motif (CTTAATAATTlTGCATAC
CCTCAGATC; lanes 2 and 5) but not by inclusion of 66 ng
of a nonspecific oligonucleotide (CCTCCAAAGAGTCAT
CAGAAGAGGAAAT; lanes 3 and 6). These data suggested
that octamer-binding proteins were capable of recognizing at
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FIG. 2. Analysis of complexes that form with enhancer sequences from the IL-2 gene. Gel mobility shift assays were performed by using
the VH probe (A), the proximal IL-2 probe (B), and the distal IL-2 probe (C). The specific activity of each probe was approximately 450
,uCi/mmol (1,000 cpm/fmol). Complexes were formed by using 500 ,ug of nuclear extract from Jurkat T cells (lanes 1 to 3), 120 ,ug of nuclear
extract from BJA/B cells (lanes 4 to 6), and 500 jig of nuclear extract from HeLa cells (lanes 7), and the formation of complexes was challenged
by inclusion of 20 ng of octamer oligonucleotide (lanes 2 and 5) or nonspecific oligonucleotide (lanes 3 and 6). FP, Free probe.
least two sites in the enhancer of the IL-2 gene. Based on the
amount of complex formed in this assay and the similar
specific activities of the three probes used, the predicted
affinities of each site for octamer-binding proteins would be
VH probe > IL-2 proximal probe > IL-2 distal probe.
Recombinant Oct-2 binds at least two sites in the IL-2
promoter. The ability of an octamer-binding protein to
interact directly with the proximal and distal IL-2 probes
was tested by incubation with Oct-2 protein, synthesized in
bacteria as a fusion with protein A (17). The Oct-2 protein
was used here for convenience; Oct-1 and Oct-2 have
indistinguishable binding specificities. The VH probe, as well
as both the proximal and distal IL-2 probes, formed com-
plexes with recombinant Oct-2 (Fig. 3, lanes 1, 4, and 7) that
were dissociated by inclusion of 20 ng of octamer oligonu-
cleotide (lanes 2, 5, and 8), but not by addition of 66 ng of
nonspecific oligonucleotide (lanes 3, 6, and 9), to the incu-
bation buffer. A probe containing a high-affinity site for the
transcription factor NF-KB did not form complexes with
recombinant Oct-2 (lanes 10 to 12). This assay proved that
Oct-2 can bind to at least one site in both the proximal and
distal IL-2 probes and again suggested that the affinity of the
sites for recombinant octamer-binding protein assumed the
order VH probe > IL-2 proximal probe > IL-2 distal probe.
Antibodies to Oct-2 specifically inhibit complex formation.
The fact that recombinant Oct-2 bound specifically to sites
within two fragments of the IL-2 enhancer implied, but did
not prove, that native octamer-binding proteins in nuclear
extracts also bound these sites. This proof was obtained by
demonstrating that the factors in BJA/B nuclear extract that
bind to the proximal and distal IL-2 probes reacted with
antibody against Oct-2 (16). Antibody to Oct-2 inhibited the
formation of Oct-1, Oct-2, and Oct-2B complexes with VH
(Fig. 4, lanes 2 and 3) as well as of the corresponding
complexes formed with each IL-2 probe (Fig. 4B and C,
lanes 2 and 3). Nonspecific antibodies had no effect on the
formation of these complexes (lanes 4). The antibodies did
not cause an increase in the mobility of octamer proteins
bound to DNA; rather, they blocked the interaction between
DNA and the octamer-binding proteins, indicating that they
react with epitopes in or near the DNA-binding domain or,
alternatively, behaved as noncompetitive inhibitors.
Methylation interference and DNase I protection. The tech-
nique of methylation interference was used to determine the
exact protein-DNA contact points in the complex formed
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FIG. 3. Complex formation with use of recombinant Oct-2. Gel
mobility shift assays were performed by using the VH probe (lanes
1 to 3), the proximal IL-2 probe (lanes 4 to 6), the distal IL-2 probe
(lanes 7 to 9), and a probe containing the motif bound by NF-KB
(lanes 10 to 12). Lanes 2, 5, 8, and 11 contain 20 ng of octamer
oligonucleotide; lanes 3, 6, 9, and 12 contain 66 ng of nonspecific
oligonucleotide. C, The location at which the complex containing
recombinant Oct-2 migrates; FP, free probe.
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FIG. 4. Effect of anti-Oct-2 serum on complex formation. Gel
mobility shift assays were performed by using 120 ng of nuclear
extract from BJA/B cells (all lanes) in the presence of 0.5 p.l (lanes
2) and 0.1 ,u1 (lanes 3) of anti-Oct-2 serum or 0.5 ,ul of a control
antiserum, specific to the Abelson tyrosine protein kinase (lanes 4).
(A) VH probe; (B) proximal IL-2 probe; (C) distal IL-2 probe.
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with the proximal IL-2 probe. DNA methylated at guanine
residues on either strand of the sequence ATGTAAAACA
(-78 to -69), as well as at the intervening adenine residues,
was excluded from complex formation by Oct-i protein (Fig.
5A). This sequence varies at a single position when com-
pared with the octamer consensus sequence, ATGCA
AATNA, derived from analysis of octamer motifs in immu-
noglobulin promoters and heavy-chain enhancers. The fact
that DNA molecules containing these methylated residues
were quantitatively excluded from the Oct-1 complex dem-
onstrates that this is the only site bound by Oct-1 in the
probe. The location of this sequence is fully contained within
the binding site for NF-1L2-A, previously defined by DNase
I protection, indicating that the footprint observed over this
sequence is, at least in part, a consequence of the binding of
Oct-1. The low abundance of the Oct-i-containing complex
that formed with the distal IL-2 probe precluded conclusive
analysis of this site by methylation interference.
If the sequences protected by NF-1L2-D, as well as by
NF-1L2-A, complex with octamer-binding proteins, then
recombinant Oct-2 produced in bacteria should bind each
site and protect exactly the same nucleotides as are pro-
tected in the footprints seen using nuclear extracts. In a
DNase I protection assay, recombinant Oct-2 bound exactly
the same two sites that were protected by proteins extracted
from BJA/B nuclei (Fig. SB). The boundaries formed by
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FIG. 5. Determination of the binding sites of the octamer proteins in IL-2 sequences. (A) Pattern of methylated nucleotides in the plus or
minus strands of probes purified from the bound (B) or free (F) populations of complex 1, formed by using Jurkat nuclear extract. Dashes
designate the positions of methylated residues excluded from the bound probe; asterisks mark the locations of these residues in the DNA
sequence. (B) Patterns of DNase I cleavage of the proximal and distal IL-2 probes assayed in the presence of 20 p.g of bovine serum albumin
(lanes 1 and 4), 20 ng of recombinant Oct-2 protein (lanes 2), or 25 pI. of glycerol gradient-purified activity (see Materials and Methods) from
BJA/B cells (lanes 3).
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protection with either recombinant Oct-2 or with the activity
from partially purified BJA/B nuclear extract were likewise
identical. This experiment demonstrated that the activity in
nuclear extracts that protects each of these sites is octamer
protein. If total nuclear extracts were used, the 5' boundary
of the proximal octamer footprint was extended, suggesting
that Oct-1 plus another cellular factor bind adjacent sites in
this sequence. Nuclear extracts purified by affinity to hep-
arin exhibited a much reduced footprint over the octamer
sequence and a much stronger footprint over the immediate
5' region (data not shown). The 5' footprint was observed in
extracts from Jurkat T cells as well as from HeLa cells and
is therefore likely to be caused by a ubiquitous transcription
factor.
Relative affinities of octamer sites. Oligonucleotides con-
taining the VH, IL-2 proximal, and IL-2 distal octamer
sequences were used to compete with the VH and proximal
IL-2 probes for binding to NF-IL2-A and Oct-1, respec-
tively. If Oct-1 binds each probe, then an oligonucleotide
competitor should exhibit equivalent half-maximal inhibition
on complex formation (Ki) between Oct-1 and any octamer-
containing probe, regardless of the affinity of the octamer
sequence contained within that oligonucleotide. In similar
fashion, since the Ki of each oligonucleotide is a unique
reflection of its affinity for the DNA-binding site of Oct-1,
oligonucleotides having strong or weak affinities should
exhibit parallel values of Ki for any two octamer-containing
probes. If, however, a protein other than Oct-1 bound this
motif, the Ki for a single oligonucleotide would likely vary
between competition experiments conducted with the VH-
Oct-1 interaction and with the proximal IL-2 probe-second-
factor interaction. The Ki of each competitor was examined
for the VH and proximal IL-2 probes (Fig. 6). When the Ki of
any one of the three oligonucleotides was determined for
both probes, the values were almost identical. These data
suggested that the identity and stability of the constellation
of amino acids that form the DNA-binding site of NF-IL2-A
and Oct-1 are likewise identical or almost identical. If
different members of the family of octamer-binding proteins
have identical contacts between amino acid side chains and
DNA, they could exhibit identical affinities for octamer
sequences. Consequently, the competition study for NF-
IL2-A, as well as the footprinting and immunological studies
for both NF-IL2-A and NF-IL2-D, place each in the family
of octamer-binding proteins, and the comigration of each
with an Oct-i-containing complex strongly suggests that
each is Oct-1 itself. However, the three oligonucleotides
exhibited distinctly different values of Ki, corresponding to
1.2, 1.9, and 16 nM for the octamer sequences in VH,
proximal IL-2, and distal IL-2 DNAs, respectively. Conse-
quently, the proximal and distal IL-2 octamer sequences
have affinities 0.63 and 0.075 times as strong as that of the
VH octamer sequence, a result consistent with the predicted
order of affinities based on gel shift analysis.
Both octamer sequences affect the induciblity of the IL-2
enhancer. The functional significance of each octamer se-
quence in the IL-2 enhancer was assessed by creating
mutations that substantially reduced their interaction with
octamer proteins and assaying the ability of each mutant
enhancer to direct transcription of the CAT gene in response
to treatment of transfected cells with TPA plus PHA. The
vector pIL2fosCAT was created to test the normal activity
of the IL-2 enhancer; it contains residues -325 to -51 of the
IL-2 promoter fused to nucleotides -56 to +112 of the fos
promoter, which is followed by the CAT gene. As first
reported by Durand et al. (6), these IL-2 enhancer sequences
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FIG. 6. Determination of relative affinities between the proximal
and distal IL-2 octamer sites, the VH octamer sequence, and Oct-1.
Complexes between Oct-1 and the VH and proximal IL-2 probes
were measured in the presence of a 0.2- to 55-ng/ml concentration of
double-stranded oligonucleotide CTTAATAATTTGCATACCCTC
AGATC (containing an immunoglobulin heavy-chain enhancer oc-
tamer sequence and designated VH), CATATGTGTAAGGCC
TAAAACATT'TTGAC (containing the proximal IL-2 octamer and
designated proximal IL2 oligo), and CAGCTCTAATTCATGCA
ATTAACGCCTTC (containing the distal IL-2 octamer sequence
and designated distal IL2 oligo). The oligonucleotides containing the
proximal and distal IL-2 octamer sequences contained TCGA single-
stranded 5' leaders to facilitate cloning into XhoI and Sain sites. The
DNA-protein complexes were separated by electrophoresis through
4% nondenaturing polyacrylamide gels, and the radioactivity in the
Oct-1 complex was quantitated by scintillation counting. Symbols:
*, values obtained with the VH probe; 0, values obtained with the
proximal IL-2 probe.
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FIG. 7. Determination of the effect of Oct-2 expression on stimulation of the IL-2 enhancer by TPA and by TPA plus PHA. Jurkat T cells
were transfected with 15 p.g of pIL2CAT per ml. The amount of cotransfected Oct-2 expression plasmid is designated below the vertical bars
and varied from 0.01 to 7.0 ,ug/ml. Numbers above the bars represent the stimulation above control values for that set of conditions. In panel
A, cells were stimulated with TPA alone, 80 p.g of extract was used for CAT assays, and incubation with substrate was allowed to proceed
for 2.0 h. In panel B, cells were stimulated with TPA plus PHA, 20 ,ug of cellular extract was used, and the incubation time was 1.0 h.
directed TPA-plus-PHA-dependent CAT transcription.
Three point mutations were introduced into in each octanu-
cleotide motif in pIL2fosCAT. The mutation at the proximal
site converted the sequence ATGTAAAACA to GCC
TAAAACA, and that at the distal site converted the se-
quence ATGCAATTAA to CGGAAATTAA. As a conse-
quence of mutation, the binding of Oct-1 to the proximal site
was reduced at least 50-fold, and that to the distal site was
reduced at least 10-fold when assayed by gel mobility shift
analysis. These mutations in the proximal and distal octamer
sites diminished the response of the IL-2 enhancer to TPA
plus PHA by 54 and 34%, respectively (data not shown).
Thus, each site is functionally important but neither is
absolutely required.
Expression of Oct-2 permits induction of the IL-2 promoter
by TPA alone and potentiates induction by TPA plus PHA. By
contrast to Jurkat T cells, the mouse T-cell line EL4 ex-
presses large quantities of Oct-2 in addition to Oct-1 (38; L.
Corcoran, unpublished observation). EL4 cells also differ
from Jurkat cells in their ability to induce efficient IL-2 gene
transcription in response to TPA alone (10). One reason why
stimulation of the IL-2 gene in EL4 cells might be accom-
plished in the absence of the PHA-mediated signal is that
Oct-2 substitutes for this signal, possibly by binding directly
to the IL-2 octamer sites normally occupied by Oct-1. By
comparison with the distal octamer sequence in the human
IL-2 promoter (ATGCAATTAA), the corresponding se-
quence of the murine IL-2 promoter, ATACAATiAA,
differs at nucleotides 3 and 8 and is not bound by nuclear
factors when analyzed by a DNase I protection assay (32).
However, the sequence of the proximal octamer motif is
identical in the promoters of both species. A large footprint
encompassing 31 bp containing the proximal octamer se-
quence has been observed in DNase I footprinting studies of
the murine IL-2 promoter (32); consequently, if Oct-2 bound
directly to the murine promoter, it would likely do so at the
proximal site. To determine whether expression of Oct-2
would alter the induction of expression from the human IL-2
promoter, we constructed a second vector, pIL2CAT, which
contains residues -550 to +51 of the IL-2 promoter followed
by the CAT gene. In Jurkat T cells, transcription of
pIL2CAT was stimulated 1.2-fold by TPA (0.2-fold increase
over background; Fig. 7A). TPA-stimulated transcription of
pIL2CAT was then tested in the presence of a cotransfected
Oct-2 expression plasmid (23; Fig. 7A). Cotransfection of the
Oct-2 expression vector with pIL2CAT resulted in a 17-fold
increase (1.2 to 20.9) in TPA-mediated stimulation of tran-
scription, whereas the basal level of transcription from
pIL2CAT was unaffected. Under these assay conditions,
cells transfected with pIL2CAT and stimulated with TPA
plus PHA produced a 140-fold induction (n = 3) in CAT
activity. Therefore, cells containing Oct-2 were capable of
transcribing the IL-2 gene in response to TPA treatment at a
level 12% that induced by both TPA plus PHA. Clearly,
Oct-2 did not substitute fully for the PHA-responsive path-
way.
To determine whether Oct-2 substituted for a PHA-in-
duced signal or instead evoked a superinduction of transcrip-
20.9
16.3
6.24
1.20
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tion by synergizing with normal cellular stimuli, we tested
whether Oct-2 expression had multiplicative effects on in-
duction by TPA plus PHA. Cotransfection of the Oct-2
expression vector with pIL2CAT synergized strongly with
induction by TPA plus PHA, increasing stimulated transcrip-
tion 13-fold (Fig. 7B). Consequently, Oct-2 enhances tran-
scription through a mechanism independent of those utilized
by TPA plus PHA. Because of the powerful transcriptional
effect mediated by Oct-2, we found it necessary to reduce
the amount of extract (fourfold) and the duration of the assay
(twofold) to maintain the linearity of the assay. Because a
large proportion of the control radioactivity measured in
extracts from uninduced cells arises from impurities in the
['4C]chloramphenicol, the control values remained essen-
tially the same while the activity values were reduced by a
factor of 8. Consequently, the calculated values for tran-
scriptional induction by TPA and PHA were reduced from
140-fold to 18-fold under these conditions. When CAT
activity was measured under standard conditions (80 ,ug of
cell extract and a 2-h incubation), extracts from cells co-
transfected with pIL2CAT and the Oct-2 expression vector
and stimulated with TPA plus PHA yielded values well
beyond the linear range of the assay (>95% conversion to
acetylated chloramphenicol). However, to determine
whether cotransfection of the Oct-2 expression plasmid
affected the efficiency of pIL2CAT uptake, standard condi-
tions were used to examine background CAT activity con-
tained in cytosolic extract derived from unstimulated cells.
Regardless of the concentration of cotransfected Oct-2
expression plasmid, background CAT activity did not vary,
indicating that inclusion of the Oct-2 expression plasmid did
not affect the transfection efficiency of pIL2CAT.
DISCUSSION
These data demonstrate that the nuclear factors NF-1L2-A
and NF-IL2-D are almost certainly Oct-1, based on the facts
that their binding affinities and specificities for octamer-
containing DNA fragments are identical to those of Oct-1
and that they are each physically and immunologically
indistinguishable from Oct-1. The sites bound by Oct-1 in the
IL-2 promoter were localized by methylation interference
and footprint analysis to the proximal sequence 5'-ATGT
AAAACA-3' (-69 to -78) and the distal sequence 5'-
TTAATTGCAT-3' (-247 to -256). Mutation of each site
resulted in a moderate inhibition of transcriptional stimula-
tion by TPA plus PHA, indicating that each site contributes
to the positive regulation of the IL-2 gene, but neither is
essential for activation in Jurkat T cells by TPA plus PHA
when transcription is driven by the -51 to -321 IL-2
enhancer. It is also possible that the biological induction of
the IL-2 gene in vivo requires octamer-binding proteins,
whereas during induction by TPA plus PHA, the octamer
motifs are less important. The elimination of single factor-
binding sites from complex enhancers does, however, often
result in marginal effects on transcription. For instance,
mutation of any of the E-box motifs or the octamer site
within the murine heavy-chain ,u700 enhancer fragment
reduces its ability to enhance transcription in B cells by less
than 50% in each case (18). During the preparation of this
report, Shibuya and Taniguchi (35) reported that each of
these sites may bind octamer or octamerlike proteins. This
suggestion has proven correct in light of our results.
In Jurkat T cells, which normally express only Oct-1, the
transcriptional response of the IL-2 promoter to either TPA
or TPA plus PHA was potentiated by expression of Oct-2.
Oct-2 expression permitted a transcriptional response to
TPA alone; however, its presence did not interfere with the
normal cellular PHA-responsive pathway, because com-
bined treatment with TPA plus PHA was much more effec-
tive in inducing transcription in the presence of Oct-2 than
was treatment with TPA alone. In this sense, the effects of
introducing Oct-2 by plasmid transfection or of removing the
Oct-i-binding site by mutagenesis had parallel effects: both
changed the magnitude of TPA-plus-PHA-stimulated tran-
scription without altering the synergistic effect of both
compounds. Previous studies have demonstrated that Oct-1
and Oct-2 have very different effects on transcription. In B
cells, which contain Oct-2, transcription of transfected genes
can be activated by inserting octamer sequences 5' of their
transcription initiation sites (42). Although these same DNA
constructs are transcriptionally inactive in cells containing
Oct-1 but not Oct-2, transcription can be induced by the
coexpression of a plasmid encoding Oct-2 (23). This effect is
thought to be mediated by direct binding of Oct-2 at the
inserted octamer site. Therefore, one explanation that ac-
counts for the mechanism by which Oct-2 affects transcrip-
tion through the IL-2 enhancer is that Oct-2 binds directly to
the proximal and distal octamer sites. Since the proximal site
is contained within a PHA-responsive 30-bp sequence, bind-
ing of Oct-2 at this location could provide a constitutive
activation function, partially circumventing the requirement
for PHA and causing the IL-2 promoter to become respon-
sive to TPA alone. A second possibility is that Oct-2 titrates
out a PHA-responsive repressor without binding the IL-2
promoter sequences directly, thereby permitting activation
by TPA alone. Finally, Oct-2 may activate transcription of
other genes, whose protein products circumvent the abso-
lute requirement for the signal induced by PHA. Regardless
of the manner by which Oct-2 affects transcription from the
IL-2 promoter, these data suggest that at least part of the
ability of the IL-2 promoter to be induced by TPA alone in
EL4 cells is a consequence of the high level of Oct-2 that is
expressed in these cells.
The stimulatory effect of Oct-2 on IL-2 promoter-mediated
expression was not evident in the absence of either TPA or
PHA. Consequently, the IL-2 promoter may also bind a
repressor that requires a TPA-mediated cellular signal for
derepression and is dominant to the activating function of
Oct-2.
In contrast to mouse EL4 cells, human Jurkat T cells
contain no Oct-2 protein, as assayed by gel mobility shift
analysis either before or after stimulation with TPA plus
PHA (M. Kamps, unpublished data). Oct-2 is therefore
unlikely to be involved in T-cell activation by TPA plus PHA
in these cells; however, we cannot eliminate the possibility
that Oct-2 is induced by mediators of T-cell activation in
vivo. Although evidence supporting a normal role of Oct-2 in
T-cell proliferation is lacking, constitutive expression of
Oct-2 in the human T-cell line Molt-4 (31) is implicated in the
abnormal expression of immunoglobulin genes in these cells.
In this context, it is possible that cellular transformation as
well is facilitated by expression of Oct-2. For instance, in
light of our evidence that Oct-2 can potentiate the production
of IL-2, which induces the proliferation of quiescent T cells,
mutations that lead to the expression of Oct-2 might repre-
sent one of multiple genetic lesions required to activate
constitutive transcription of the IL-2 gene, producing a
T-cell leukemia via autocrine growth stimulation.
In contrast to these results and those of Durand et al. (6),
the proximal IL-2 octamer site itself was found to behave as
a transcriptional repressor in CAT vectors containing the
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simian virus 40 enhancer, positioned 5' to the IL-2 promoter
(25). It is likely, however, that mutation of the proximal
octamer site in these vectors, which increased the basal
levels of CAT expression in T cells, did so by permitting
more efficient readthrough transcription from cryptic initia-
tion sites in the simian virus 40 enhancer rather than by
allowing increased transcription from the normal start site.
Indeed, using constructs containing the CAT gene under
control of the IL-2 promoter alone, Zhang and Nabel find
that mutation of the proximal octamer site diminishes sub-
stantially the ability of the construct to stimulate transcrip-
tion in response to the addition of TPA and PHA (L. Zhang
and G. Nabel, personal communication). Our results are
consistent with the earlier results of Durand et al. (6), which
were based on deletion analysis. They observed a 95 and
59% diminution in activation potential of an IL-2 promoter
CAT construct after deleting 10 and 38 bases encompassing
the proximal and distal octamer sites, respectively. The
larger effects on transcription may be due to removal of
additional factor-binding sequences within these deletions.
Alternatively, the differences between their data and ours
may be a consequence of examining enhancer mutation in
the context of two different promoters, the IL-2 promoter in
the investigations of Durand et al. and the fos promoter in
our own studies. To clarify the larger effects of deletions in
these regions, a more detailed mutational study, aimed at
understanding the functional organization surrounding each
octamer sequence, will be required.
The finding that each octamer site is important in achiev-
ing complete activation of the IL-2 gene suggests a potential
function for the ubiquitous octamer protein in coordinating
efficient signal transduction. Although the proximal octamer
sequence is itself contained within a PHA-responsive ele-
ment (6), simple multimerization of an octamer-binding site
alone is insufficient to create a PHA-responsive element,
because multimers encompassing the distal octamer se-
quence do not direct PHA-stimulated transcription (6).
Therefore, other transcription factors independently, or in
concert with Oct-1, probably account for the PHA respon-
siveness of the -65 to -95 DNA sequence in the IL-2
promoter. In fact, we have observed that a second factor,
contained in nuclear extracts from both HeLa and Jurkat
cells, binds a sequence just 5' to the proximal octamer site
(unpublished data). Mutational analysis can now be per-
formed to clarify the activities of Oct-1 and this second
factor in PHA-induced transcription.
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